AMR – From G20 Commitments to Measurable Action

The Global Business for Health Partnership will bring together senior representatives from G20 governments, global health leads and industry to discuss the policy challenge of antimicrobial resistance (AMR). The UN Ad hoc Interagency Coordinating Group on Antimicrobial Resistance has warned that drug-resistant diseases could cause 10 million deaths each year by 2050 and catastrophic damage to the global economy. By 2030, antimicrobial resistance could force up to 24 million people into extreme poverty.

The COVID-19 experience strongly indicates that international policy preparedness cooperation is an essential precondition for addressing the “silent pandemic” of AMR. The One Health Global Leaders Group on AMR, and its action plan, drives concrete action by governments and other responsible stakeholders. The UK G7 Summit and relevant Health, Environment & Finance Ministerial communiqués point to the need for immediate global action on AMR and engagement between policymakers and the international private sector.

Format & Theme

The event aims to inform G20 discussions on AMR, express support for continued G20 work, highlight recent progress, provide recommendations on taking forward existing G20 commitments on AMR, and ensure AMR remains on the G20 agenda throughout the next few years. This event will follow the G7 Leaders’ Summit (11-13 June) and 3^rd G20 Health Working Group Meeting (17-18 June), in anticipation of further concrete G20 health discussions before the 5-6 September G20 Health Ministerial.

The virtual discussion will take place on July 7, 10:00AM - 11:30AM EST (16:00 - 17:30 CEST) including Q&A with participants. The event will feature two interactive panels comprising representatives from Government(s), AMR Experts, and Industry. The discussion will focus on measuring G20 progress on AMR, tracking best practices, and developing the necessary tools and technologies to effectively address AMR.

Agenda

Opening Keynote – Prof. Silvio Brusaferro, President of the Italian Institute of Health (Istituto Superiore Sanità)
Introduction by Host & Moderator – Sally Davies, UK Special Envoy on AMR
Panel Discussion 1: Economic Challenges of Innovation and Recent Efforts
- Themes explored: The economic challenge of AMR innovation and the need for novel solutions – highlight contributions by the industry, as well as recent efforts undertaken by governments (including US PASTEUR, DISARM), and discuss the role of the G20.
  
  Participants:
  - James Anderson, Executive Director, IFPMA
  - Lav Agarwal, Joint Secretary of the Ministry of Health, India
  - Dr. Lynn Filipi, AMR Team Lead, U.S. Department of Health and Human Services
  - Dr. Henry Skinner, CEO, AMR Action Fund
  - Dr. Pol Vandenbroucke, Chief Medical Officer, Pfizer Hospital Business Unit
  - Veda Poon, Director, International Finance, HM Treasury, UK
Panel Discussion 2: The Broader Challenge of AMR to LMICs and G20 Action
- Themes explored: Awareness raising of the impact of AMR and the challenges faced by G20 (including LMICs), focusing on stewardship and access – explore G20 efforts and the role of various stakeholders in tackling the challenge.
  
  Participants:
  - Jan Van Acker, President of Emerging Markets, MSD
  - Dr. Martin Fitchet, Head, Global Public Health, Johnson & Johnson
  - Dr. Hosam Zowawi, Group Leader & Asst. Professor of Clinical Microbiology, King Saud bin Abdulaziz University; Honorary Fellow, University of Queensland
  - Dr Seamus O’Brien, R&D Director, GARDP
Q&A Session with Audience
Conclusion by the Moderator